{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:08:35Z","timestamp":1780438115935,"version":"3.54.1"},"reference-count":75,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2019,3,4]]},"DOI":"10.1080\/13543784.2019.1568989","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T03:59:12Z","timestamp":1547524752000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["New drugs under investigation for the treatment of alopecias"],"prefix":"10.1080","volume":"28","clinical-trial-number":[{"clinical-trial-number":"nct03137381","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03532958","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03359356","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02299297","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02684097","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03315689","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03651752","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02553330","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02684123","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02974868","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03354637","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02018042","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03594227","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03570749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02561585","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jorge","family":"Ocampo-Garza","sequence":"first","affiliation":[{"name":"Dermatology Department, University Hospital \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n","place":["Monterrey, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-0228","authenticated-orcid":false,"given":"Jacob","family":"Griggs","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.03030.x"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0077-5"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1103442"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.1141"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10955.x"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0542-7"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.032"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.007"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.006"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479722"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2018.1444750"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.02.015"},{"key":"e_1_3_4_20_1","first-page":"5","article-title":"Janus kinase\n      inhibitors: a review of their emerging applications in dermatology","volume":"23","author":"Cinats A","year":"2018","unstructured":"Cinats A, Heck E, Robertson L. Janus kinase inhibitors: a review of their emerging applications in dermatology. Skin Therapy Lett. [Internet]. 2018 [cited 2018 Nov 2];23:5\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29772037","journal-title":"Skin Therapy Lett"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-14-298"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38779"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.013"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.272"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205847"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0932-2"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500973"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.043"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.4445"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.07.018"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.024"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14192"},{"key":"e_1_3_4_36_1","unstructured":"LEO Pharma. Clinical trial report synopsis - efficacy of twice daily applications of LEO 124249 ointment 30mg\/g for 12 weeks to subjects with alopecia areata [Internet]. 2017 [cited 2018 Nov 5]. Available from: http:\/\/www.leo-pharma.com\/Home\/Research-and-Development\/Clinical-trial-disclosure\/Clinical-trial-summaries-and-reports\/Clinical-trial-search\/Alopecia-areata.aspx."},{"key":"e_1_3_4_37_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2340\/00015555634952","article-title":"Diphencyprone in\n      the treatment of alopecia areata","volume":"63","author":"Happle R","year":"1983","unstructured":"Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol. [Internet]. 1983 [cited 2018 Nov 3];63:49\u201352. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6191489","journal-title":"Acta Derm Venereol"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12776"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2015.32"},{"key":"e_1_3_4_40_1","first-page":"300","article-title":"Treatment of\n      therapy-resistant Alopecia areata with fumaric acid esters","volume":"11","author":"Venten I","year":"2006","unstructured":"Venten I, Hess N, Hirschm\u00fcller A, et al. Treatment of therapy-resistant Alopecia areata with fumaric acid esters. Eur J Med Res. Internet]. 2006 [cited 2018 Nov 2];11:300\u2013305. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16899425","journal-title":"Eur J Med Res"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2018.3249"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0775-4"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S148586"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12934"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.11.009"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.034"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2976"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.11.020"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-018-0151-5"},{"key":"e_1_3_4_51_1","article-title":"Treatment of\n      atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb","author":"Wollenberg A","year":"2018","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb. J Allergy Clin Immunol. [Internet]. 2018 [cited 2018 Nov 2]; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29906525","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0379.2011.07802.x"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1992.tb00121.x"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S6480"},{"key":"e_1_3_4_55_1","volume-title":"ClinicalTrials.gov","author":"Duke University","year":"2000","unstructured":"Duke University. Topical bimatoprost effect on androgen dependent hair follicles. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2018 Nov 3]. [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01325350NLMIdentifier:NCT01325350"},{"key":"e_1_3_4_56_1","volume-title":"ClinicalTrials.gov","author":"Allergan","year":"2000","unstructured":"Allergan. Safety and efficacy study of bimatoprost in the treatment of women with female pattern hair loss. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2018 Nov 3]. [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01325350NLMIdentifier:NCT01325350"},{"key":"e_1_3_4_57_1","volume-title":"ClinicalTrials.gov","author":"Allergan","year":"2000","unstructured":"Allergan. Safety and efficacy study of bimatoprost in the treatment of men with androgenic alopecia. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2018 Nov 3]. [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01325337NLMIdentifier:NCT01325337"},{"key":"e_1_3_4_58_1","volume-title":"ClinicalTrials.gov","author":"Allergan","year":"2000","unstructured":"Allergan. A safety and efficacy study of bimatoprost in men with androgenic alopecia (AGA). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Nov 3]. [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01904721NLMIdentifier:NCT01904721"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.05.026"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.2147\/SCCAA.S138150"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003122"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-017-0183-z"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-018-1826-8"},{"key":"e_1_3_4_64_1","unstructured":"Yazici Y Swearingen CJ Simsek I et al. Safety tolerability and efficacy of a topical treatment (sm04554) for androgenetic alopecia (aga): results from a phase 2 trial. Poster session presented at: American Academy of Dermatology (AAD); 2016 March 04\u201308; Washington (DC)."},{"key":"e_1_3_4_65_1","unstructured":"Seykora J Simsek I DiFrancesco A et al. Safety and biopsy outcomes of a topical treatment (sm04554) for male androgenetic alopecia (aga): results from a phase 2 multicenter randomized double-blind vehicle-controlled trial. Poster session presented at: American Academy of Dermatology (AAD); 2017 March 03\u201307; Orlando (FL)."},{"key":"e_1_3_4_66_1","unstructured":"Samumed. Monthly newsletter. 2018 Aug [Internet]. [cited 2018 Nov 2]. Available from: https:\/\/www.samumed.com\/medium\/image\/monthly-newsletter-2018-7_387\/view.aspx"},{"key":"e_1_3_4_67_1","unstructured":"Cassiopea. Creating innovation in dermatology. Presented at: jefferies Global Health Care Conference; 2016 June 9; New York (NY); Available from: http:\/\/www.cassiopea.com\/~\/media\/Files\/C\/Cassiopea\/presentations\/Jefferies_GHCC_Jun2016.pdf"},{"key":"e_1_3_4_68_1","unstructured":"Cassiopea. Breezula [Internet]. [cited 2018 Nov 2]. Available from: http:\/\/www.cassiopea.com\/activities\/product-pipeline\/breezula.aspx"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202467"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15171"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0128-0"},{"key":"e_1_3_4_72_1","unstructured":"The Belgravia Center. Pfizer \u2018Breakthrough\u2019 JAK inhibitor for severe alopecia areata [Internet]. 2018 [cited 2019 Jan 1]. Available from: https:\/\/www.belgraviacentre.com\/blog\/pfizer-breakthrough-jak-inhibitor-for-severe-alopecia-areata\/"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0312-y"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.018"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2017.107"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1159\/000494690"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1049641"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2019.1568989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:21:55Z","timestamp":1772716915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2019.1568989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,4]]}},"alternative-id":["10.1080\/13543784.2019.1568989"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2019.1568989","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}